Northpond Ventures
Venture capitalBethesda · Seed–Series A · 39 people tracked
Also known as NORTHPOND VENTURES, LLC
Find your way into Northpond Ventures
2,418 people in our graph share verified history with the Northpond Ventures team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Embeds multi‑year research programs at top institutions, co‑runs labs and project selection, then converts academic IP into startups through negotiation, incorporation and syndication; focuses on tools, platforms and biomanufacturing.
Source: firm website, verified Sep 15, 2026.
Team · 39 people
from the firm's website & curated & public directories
What they invest in
from 46 of 59 portfolio companiesBiotech ×32Healthtech ×25AI & Machine Learning ×19Medical Devices ×19Deep Tech ×16Digital Health ×10Hardware ×5SaaS ×5
HQs:United States×41United Kingdom×2Australia×1Brazil×1
Investments · 59 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 62024 · 32023 · 32022 · 152021 · 102020 · 32019 · 32018 · 147 dated
908 Devices manufactures handheld mass spectrometry and chemical analysis devices for rapid detection in defense, security, and hazardous materials response applications.
Deep TechDefense TechHardwareMedical DevicesBoston, US
Kevin J. Knopp, PhD(CEO & Co-founder)Christopher Brown(Executive Officer)inKevin Knopp(Executive Officer, Director)inJoseph Griffith IV(Executive Officer)
BoardKevin Hrusovsky(Director)Corey Steffek(Director)
Board seatSharon Kedar· per SEC Form D
Co-investorsARCH Venture PartnersRazor's Edge VenturesUTECAramco VenturesARK Investment ManagementBlackRock
Vizgen develops high-throughput spatial profiling technologies, including MERFISH-based spatial genomics and spatial proteomics tools for life science research and precision oncology.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesCambridge, US
George Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)inJiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)inXiaowei Zhuang(Founder; Professor, Harvard University)inFenel Eloi(Director)Rob Carson(Chief Executive Officer)inSimona Levi(Chief Legal Officer)in
Board seatSharon Kedar· per SEC Form D
Co-investorsARCH Venture Partners6 Dimensions CapitalAlly Bridge GroupApplied VenturesKilonova CapitalPura Vida Investments+3 more
Emulate builds Organ-on-a-Chip systems, including platforms, consumables, and pre-assembled BioKits with validated human cell models, to support drug discovery research.
BiotechDeep TechHealthtech
Donald Ingber(Scientific Founder, Board Member, Scientific Advisory Board Chairman)inDaniel Levner(Co-Founder & CTO)inJim Corbett(CEO, Board Member)inLorna Ewart(Chief Scientific Officer)in
Co-investors+ND CapitalAlwyn CapitalFourth RealmStray Dog CapitalOS FundStarlight Ventures
Inflammatix develops host-response-based molecular diagnostics tests to identify acute infections and sepsis in emergency and critical care settings.
AI & Machine LearningBiotechHealthtechMedical DevicesBurlingame, US
Tim Sweeney(Co-Founder and CEO)inPurvesh Khatri(Co-Founder and Chief Scientist)inJONATHAN ROMANOWSKY(Executive Officer)in
BoardKENNETH BAHK(Director)MICHAEL RUBIN(Director)DAVID PERSING(Director)
Co-investorsKhosla VenturesInitiate Venture PartnersOSF VenturesDFJ
Mestag is an immunology company developing first-in-class treatments for cancer and inflammatory diseases by leveraging novel understanding of fibroblast biology and tertiary lymphoid structures.
AI & Machine LearningBiotechDigital HealthHealthtechLondon, GB
Michael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)inSoumya Raychaudhuri(Founder)David A. Tuveson(Founder)Susan Hill(Chief Executive Officer)in
Co-investorsSV Health InvestorsForbionGV (Google Ventures)
Mestag Therapeutics is an immunology company developing first-in-class agonist antibody therapies for cancer and inflammatory diseases based on fibroblast biology, and operates a RAFT platform for discovering new drug targets.
AI & Machine LearningBiotechHealthtech
Susan Hill(Chief Executive Officer)inMichael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)inSoumya Raychaudhuri(Founder)David A. Tuveson(Founder)
Co-investorsGV (Google Ventures)ForbionJohnson & Johnson Innovation – JJDCSV Health InvestorsJJDC
Octave develops blood-based biomarker tests for neurodegenerative diseases including multiple sclerosis, Parkinson's disease, and Alzheimer's disease.
AI & Machine LearningBiotechDigital HealthMedical DevicesMenlo Park, US
William Hagstrom(Founder and Chairman)inDoug Biehn(President and CEO)in
Co-investorsSandbox IndustriesSection 32Blue Venture FundsEcho Health VenturesHikma VenturesGreycroft+1 more
OMass is a biotech company that originated as a spinout from Oxford University, developing specialized treatments for patient populations with high unmet medical needs.
BiotechDeep TechDigital HealthHealthtechMedical DevicesOxford, GB
Professor Dame Carol Robinson(Founder and Chair of Scientific Advisory Board)Idlir Liko(Founder)inJonathan Hopper(Vice President, Platforms and Founder)inHsin Yung (Jason) Yen(Founder)inRos Deeganin
Co-investorsGV (Google Ventures)Oxford Science EnterprisesSanofi Ventures
QbDVision provides a software platform designed to address digital transformation challenges in pharmaceutical and biotech manufacturing, helping companies manage compliance, quality, and process development.
BiotechCloud ComputingEnterprise SoftwareHealthtechSaaSAustin, US
Yash Sabharwal(President, CEO, Co-Founder)inRyan Shillington(CTO, CISO, Co-Founder)in
Co-investorsS3 VenturesCartmell VenturesCREATE HEALTH VENTURES
Transition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease.
AI & Machine LearningBiotechDeep TechCambridge, US
Tuomas Knowles(Executive Director, Co-Founder & Chief Technology Officer)Samuel Cohen(Executive Director & Co-Founder)inG. Kelly Martin(Executive Chairman & Co-Founder)George Martin(Executive Officer, Director)inStephanie Torruella(Executive Officer)inPreet Makkar(Executive Officer)
Co-investorsLifeforce CapitalMagnetic VenturesTaiho Ventures, LLCDolby Family Ventures
VitalBio develops the VitalOne, a diagnostic device that delivers comprehensive lab-grade blood test results in minutes from a small blood sample, using robotics, biochemistry, computer vision, and microfluidics.
BiotechDigital HealthMedical Devices
Vasu Nadella(Founder)in
Co-investorsNext VenturesInovia CapitalLachy GroomMarc BenioffSam Altman1955 Capital+6 more
Vizgen develops spatial profiling instruments and reagents for high-throughput analysis of gene expression and protein distribution in tissue samples.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US
George Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)inJiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)inRobert Carson(Executive Officer, Director)Terry Lo(Director)inSeth Benson(Executive Officer)inSimona Levi(Executive Officer)in
Co-investorsARCH Venture PartnersM VenturesIllumina VenturesNovalis LifeSciences
En Plus One Bio develops synthesis and manufacturing technology for RNA therapeutics, focused on producing high-purity long RNA with higher cycle efficiencies and novel chemical modifications.
BiotechDeep TechWatertown, US
Daniel Ahlstedt(Executive Officer, Director)inJonathan Rittichier(Founder)in
BoardAndrew Lee(Director)inSteven Kasok(Director)
Board seatPaxton Major· per SEC Form D
Co-investorsBreakout VenturesCoatue Management
IsoPlexis (now part of Bruker Cellular Analysis) provides single-cell functional profiling technology used to discover therapeutic antibodies, interrogate T cells for novel cell therapies, and accelerate cell line development.
BiotechDeep TechMedical DevicesNew Haven, US
Rong Fan(Director)Sean McKay(Executive Officer, Director)Sean Mackay(Executive Officer, Director)
BoardDaniel Wagner(Director)John Conley(Director)inGregory Ho(Director)
Board seatSharon Kedar· per SEC Form D · $85M raise · filed Jan 2021
Co-investorsAlly Bridge Group
64x provides a platform and product suite for manufacturing advanced therapeutics, including gene therapies, cell therapies, and biologics.
BiotechDeep TechMedical Devices
Co-investorsBoxGroupFifty YearsFirst Round CapitalFuture VenturesLifeforce CapitalRefactor Capital+1 more
64x develops infrastructure and manufacturing systems for next-generation medicines, focusing on genetic engineering, cell line development, and computational biology to enable scalability of advanced therapies.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSan Francisco, US
Lexi Rovner(Co-founder & CEO)in
Co-investorsFifty YearsFuture VenturesLifeforce CapitalRaptor GroupY CombinatorAlix Ventures+4 more
Aro is a Brazilian technology platform that connects users with over 40 regulated credit partners to find personal loans, payroll (consignado CLT) loans, phone-collateral loans, and credit for people with negative credit records.
AI & Machine LearningB2B MarketplacesFintech
Co-investorsNorte Ventures17SigmaCowen Healthcare InvestmentsOnevc Venture Partners Llc
Aro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins.
BiotechHealthtechPhiladelphia, US
Karyn O'Neil(Executive Officer, Director)Susan Dillon(Founder)inMark V. Laurenzi(Executive Officer)
BoardElizabeth Anderson(Director)Bruce Peacock(Director)
Co-investorsAvego BioScience CapitalHealthCapAgent CapitalBiotechnology Value FundCowen Healthcare InvestmentsJohnson & Johnson Innovation – JJDC
QbDVision develops a Digital CMC (Chemistry, Manufacturing, and Controls) platform that captures structured product and process data to support end-to-end product lifecycle management from R&D through commercial manufacturing.
AI & Machine LearningBiotechSaaSAustin, US
Yashvinder Sabharwal(Executive Officer, Director)Ryan Shillington(Executive Officer, Director)
Co-investorsATX Venture Partners
ChromaCode develops a High-Definition PCR (HDPCR) multiplexing platform that enables genomic solutions for oncology and precision medicine, offering faster results and cost-effective workflows through automated interpretation and cloud-based software.
AI & Machine LearningBiotechHealthtechMedical DevicesCarlsbad, US
Paul Flook(Executive Officer, Director)inGregory J. Gosch(Executive Officer, Director)Lynne Rollins(Executive Officer)Aditya Rajagopal(Director)inAxel Scherer(Director)
BoardJustin Klein(Director)in
Co-investorsAdjuvant CapitalGlobal BrainMoore Venture PartnersNew Enterprise Associates (NEA)Windham Capital PartnersDomain Associates+2 more
Code Biotherapeutics develops a proprietary non-viral 3DNA delivery platform for genetic medicines, RNAi, and other modalities, using targeting molecules to reach specific cells and tissues outside the liver.
BiotechDeep TechHealthtechHatfield, US
Lauren Kaskiel(Executive Officer)inRobert C. Getts(Executive Officer)Brian McVeigh(Executive Officer, Director)in
BoardDmitry Kuzmin(Director)Victor Stone(Director)Edward Mathers(Director)
Co-investorsNew Enterprise Associates (NEA)4BIO CapitalAmgen VenturesHatteras Venture PartnersJDRF T1D FundTakeda Ventures+1 more
Culture Biosciences provides software and bioreactor hardware solutions for bioprocess development, enabling researchers to design, monitor, and analyze experiments remotely with cloud-native analytics and AI/ML insights.
AI & Machine LearningBiotechCloud ComputingHealthtechSan Francisco, US
Will Patrick(Founder/CEO)inMatt Ball(Founder/CTO)in
Co-investorsCompoundDCVC (Data Collective)GRIDS CapitalHemisphere Ventures LLCThe E14 FundY Combinator+4 more
Current Health builds FDA-cleared clinical technology and infrastructure that enables acute and complex care—including advanced therapies like CAR-T, bispecifics, and cell and gene therapies—to be delivered safely in ambulatory and home settings.
AI & Machine LearningDigital HealthHealthtechMedical DevicesEdinburgh, US
Christopher McGhee(Founder)in
Co-investorsLRVHealthMMC VenturesOSF VenturesSection 32
Columbus, US
Tim Bowen(Executive Officer, Promoter)Dave Billiter(Executive Officer, Director, Promoter)inSimon Arkell(Executive Officer, Promoter)in
BoardMark Shary(Director)inJeffrey Elton(Director)
Co-investorsTamarind HillRev1 VenturesSierra Ventures
Eleanor Health is an outpatient addiction treatment program that delivers remote evidence-based care for substance use disorder, including medication-assisted treatment and counseling.
Digital HealthHealthtechMental HealthWaltham, US
Dr. Nzinga Harrison(Chief Medical Officer and Co-founder)Corbin Petro(Executive Officer, Director)Srishti Mirchandani(Executive Officer)in
BoardDavid Whelan(Director)inSonny Goyal(Director)Kurt Sheline(Director)in
Co-investorsEcho Health VenturesRethink ImpactTown Hall VenturesGeneral CatalystWarburg Pincus
.png)
Elephas develops elive, a live-tissue platform technology that predicts immunotherapy response in cancer patients by measuring real-time immune activity in intact tumor tissue.
BiotechDigital HealthHealthtechMedical DevicesMadison, US
Jonathan Oliner(Executive Officer)inManeesh Arora(Founder)inMichelle B. Arora(Director)Terrence P. Brady(Executive Officer)
Co-investorsARCH Venture PartnersSands Capital Ventures
San Diego protein-sequencing company behind the ProteoCode platform; ceased operations in late 2025.
Co-investorsARCH Venture PartnersDecheng CapitalAlexandriaDeerfield Management CompanyGV (Google Ventures)Nan Fung Life Sciences
General Inception is an operational support and company building firm that handles day-to-day planning and execution for building companies, with a focus on life science tools and diagnostics.
Deep TechHealthtechMedical Devices
Co-investorsOMX VenturesPaladin Capital GroupGenoa VenturesVertical Venture Partners
BiotechPortola Valley, US
Lena Wu(Executive Officer, Director)Erik Gentalen(Director)Michael Rubin(Director)
BoardJenny Rooke(Director)in
Co-investorsVertical Venture PartnersGenoa Ventures
Kytopen develops non-viral gene delivery technology called Flowfect that combines fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP into cells for high-throughput transfection.
BiotechDeep TechHardwareCambridge, US
Cullen Buie(Director)inPaulo Garcia(Executive Officer, Director, Promoter)inMichael Chiu(Director, Executive Officer)in
BoardPaxton Major(Director)inAnn DeWitt(Director)inPaul Wotton(Director)
Co-investorsBantam GroupHorizons VenturesMassVenturesSelvedge VentureTBD AngelsTelegraph Hill Partners+2 more
Modern Systems Talk (MST) publishes content and insights on technology topics including system architecture, cloud computing, automation, AI, cybersecurity, and digital transformation.
Media & Entertainment
Co-investorsAgate Medical Investments LPSCP Vitalife PartnersForbionGV (Google Ventures)SV Health Investors
Opt Industries engineers advanced materials using digital photolithography to create structured materials with precise microstructure control, enabling functional properties across applications from high-speed interconnects to fluid handling.
Advanced ManufacturingDeep TechNew MaterialsMedford, US
Co-investorsCrosslink CapitalGrit VenturesThe E14 FundBlumberg CapitalGradient Ventures
Ori develops expandable-unit technology for multifamily real estate, enabling hotel-to-housing conversions and ground-up developments that increase unit density while maintaining livability.
Construction TechHardwareImpact & Social GoodPropTech
Co-investorsIngka InvestmentsPresidio VenturesThe E14 FundAmadeus Capital PartnersDelin VenturesKhosla Ventures+3 more
ORI provides an integrated business planning platform for supply chain professionals, combining demand planning, S&OP, S&OE, data analytics, and long-term planning in one tool.
AI & Machine LearningLogistics & Supply ChainSaaS
Brant Slade(Founder)in
Co-investorsKickstartAmadeus Capital PartnersDelin VenturesKhosla VenturesNovalis LifeSciencesOctopus Ventures+2 more
Ori Biotech develops manufacturing automation platforms for cell and gene therapies, addressing scalability and cost barriers that limit patient access to these treatments.
Advanced ManufacturingBiotechDeep TechHardwareHealthtechMedical Devices
Co-investorsAmadeus Capital PartnersKindred CapitalNovalis LifeSciencesDelin VenturesOctopus VenturesPuhua Capital
Outcomes4Me is an AI-driven patient platform that integrates with NCCN clinical oncology guidelines to provide personalized cancer care guidance, treatment options, clinical trial recommendations, and genetic testing information.
AI & Machine LearningDigital HealthHealthtechCambridge, US
Maya R. Said(Founder and CEO)inOsama Rahma(Founder)in
BoardAndrea Jackson(Director)inDavid Fleshman(Director)David Auckland(Director)
Co-investorsAsset Management CompanyHealthX VenturesSierra VenturesAsset Management Ventures
Phia is an AI shopping assistant that compares prices across the web and secondhand marketplaces so shoppers can build their closet at the best price.
New York, US
Sophia Kianni(Co-founder)inPhoebe Gates(Co-founder)in
BoardAnnie Case(Director)in
Co-investorsCold Start VenturesDuke Capital PartnersKleiner PerkinsNotable CapitalScribble VenturesKhosla Ventures
Scitara provides cloud-based integration and data management software for scientific laboratories, enabling connection of lab instruments and applications into a unified environment with AI-powered analytics.
AI & Machine LearningBiotechData & InfrastructureSaaSMarlborough, US
Ajit Nagral(CEO & Chairman)inGeoff Gerhardt(Executive Officer, Promoter)inVinayak Purohit(Executive Officer)in
BoardCharles M. Hazard, Jr.(Director)Andrea Jackson(Director)inRohit Khanna(Director)
Co-investorsFlybridge Capital Partners
HealthtechCambridge, US
Rahul Dhanda(Executive Officer, Director)inJames Collins(Director)David Walt(Director)in
BoardIssi Rozen(Director)in
Co-investorsCatalio Capital Management, LPIllumina VenturesCatalio Capital ManagementGood VenturesGV (Google Ventures)Novalis LifeSciences
SimBioSys builds AI-powered 3D visualization and diagnostic technology that models tumors as "digital twins" to support individualized cancer treatment planning.
AI & Machine LearningBiotechDigital HealthMedical DevicesChicago, US
Joe Peterson(Co-founder)John Cole(Co-founder)Tushar Pandey(Co-founder)inStacey Stevens(Executive Officer, Director)in
BoardVikram Chaudhery(Director)inLucy Coassin(Director)
Co-investorsAV8 VenturesGenoa VenturesGENERAL INCEPTION
Slingshot Biosciences makes synthetic cell mimics used as standardized reference controls for flow cytometry and cell-based assays.
Emeryville, US
Jeff Kim(Founder)inAdam Wieschhaus(Director)Ronald J. Silberman(Director)
BoardCorey Ritter(Director)in
Co-investorsARCH Venture PartnersAnterra Capital
AgTechEmeryville, US
Eric Davidson(Director)inTravis Bayer(Director)inPaul Beck(Executive Officer)inDave Vosburg(Executive Officer)Adam Litle(Executive Officer, Director)inDerek Norman(Director)in
Co-investorsCavallo VenturesCultivian Sandbox VenturesS2G InvestmentsFall Line CapitalFootPrint CoalitionLeaps by Bayer+2 more
SpeeDx develops PCR-based diagnostic tests for sexually transmitted infections that detect pathogens and antibiotic resistance markers, enabling clinicians to make informed treatment decisions.
BiotechData & InfrastructureDigital HealthHealthtechMedical DevicesSydney, AU
Alison Todd(Co-founder)Elisa Mokany(Co-founder)in
Co-investorsTenmile
Palo Alto, US
Jonathan Hirsch(Executive Officer, Director)Glenn Winokur(Executive Officer, Director)Tony Loeser(Executive Officer)
BoardJohn Kuelper(Director)inChamath Palihapitiya(Director)Gary Kurtzman, M.D.(Director)
Co-investorsAscension VenturesSocial Capital Partnership
Telesis Bio, Inc. is a company whose corporate governance page describes its Board of Directors and governance practices.
AI & Machine LearningBiotechDeep TechHardwareHealthtechSan Diego, US
Daniel G. Gibson(Executive Officer)inTodd R. Nelson(Executive Officer, Director)Eric Esser(Executive Officer)inWilliam F. Snider(Director)Andrea L. Jackson(Director)inChristine A. Tsingos(Director)
Co-investorsNovalis LifeSciences
BiotechCambridge, US
Shawn Marcell(Executive Officer, Director)Ben Linden(Executive Officer)inDavid Yu Zhang(Director)Peng Yin(Director)
BoardAdam Wiechhaus(Director)
Co-investorsIllumina Ventures
Triumvira is a clinical-stage immuno-oncology company developing autologous and allogeneic T cell therapeutics for cancer treatment.
BiotechHealthtechMedical DevicesAustin, US
TERESA MCROBERTS(Executive Officer)inPAUL LAMMERS, MD, MSc(Executive Officer, Director)inJON IRVIN(Executive Officer)in
BoardDANIEL JANSE(Director)JURGEN ECKHARDT(Director)ELIZABETH WILLIAMS(Director)
Co-investorsB Capital GroupB4 CapitalCheckmate Capital Group LLCLeaps by BayerOceanpine Capital
.jpeg){kind=logo}
Uptime Health provides operational tools and preventive maintenance plans to healthcare practices to reduce downtime and ensure regulatory compliance.
Enterprise SoftwareHealthtechSaaSBoston, US
William Olsen(Executive Officer, Director)Jinesh Patel(Executive Officer, Director)in
BoardJohn Huysmans(Director)
Co-investorsBantam GroupC2 VenturesCaduceus Capital PartnersDIAKluz VenturesOverline+6 more
Walking Fish Therapeutics develops cell therapies aimed at restoring health and function in patients.
AI & Machine LearningBiotechHealthtechMedical DevicesSouth San Francisco, US
Lewis Williams(Co-founder & CEO)inRusty Williams(Founder)Antonin de Fougerolles(Director)Momo Wu(Director)Stella Xu(Director)Alexis Ji(Director)
Co-investorsPandect BioventuresFirst Spark Ventures, Llc
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Emulate, Inc.Merge Bio Therapeutics1859Bot-ItCove SodaFanableHawthorne EffectMitra RxDxW Labs
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 3
1 IPOs · 2 acquisitions · showing 2908 DevicesNASDAQ: MASSCurrent Healthacq. by Best Buy
Portfolio news
latest coverage across their companiesPhia · centraljersey.com · Aug 15, 2026
Telesis Bio · markets.businessinsider.com · Aug 14, 2026
Aro · altss.com · Aug 11, 2026
MST · pluang.com · Aug 10, 2026
Scitara · intelligence360.news · Jul 29, 2026
OPT Industries · fortuneindia.com · Jul 17, 2026
Octave · stocktitan.net · Jul 14, 2026
908 Devices · tradersunion.com · Jul 13, 2026
Frequently asked questions
- How many investments has Northpond Ventures made?
- Northpond Ventures has 59 tracked investments, 3 of which have exited, including 11 dated in the last 24 months.
- What stage does Northpond Ventures invest at?
- Northpond Ventures invests at the Seed, Series A stages.
- What is Northpond Ventures's typical check size?
- Northpond Ventures typically writes checks of $100K – $5M.
- What sectors does Northpond Ventures focus on?
- Northpond Ventures focuses on AI & Machine Learning, Biotech, Cleantech, Climate Tech, Deep Tech, Energy, Hardware, Healthtech, Medical Devices, Sector Agnostic.
- Where is Northpond Ventures located?
- Northpond Ventures is headquartered in Bethesda, US.
- Does Northpond Ventures lead rounds?
- Northpond Ventures typically participates in rounds rather than leading them.
Images
Co-investors · 45
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
The E14 Fund is an early-stage venture firm affiliated with MIT that invests in AI and deep-tech companies and runs an investment fellowship program for earlier-stage founders.
Genoa Ventures is a venture capital firm that works with strategic partners providing market insights, validated deal flow, and domain expertise to support its portfolio companies.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
First Round Capital is an early-stage venture firm that backs companies at their earliest moments, often before they are named, across enterprise, AI, consumer, healthcare, fintech and hardware sectors.
Sandbox Industries is an investment firm that fosters innovation in the healthcare and insurance industries, partnering with corporate strategic investors as limited partners alongside financial investors and portfolio companies.
Echo Health Ventures is a strategic venture capital and growth equity investor that partners with health care companies to help build and scale their innovations nationally.
OMX Ventures is a venture capital firm investing in life sciences and biotechnology companies, spanning therapeutics, synthetic biology, and biotools and diagnostics.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Seed-stage venture capital firm based in Boston and New York City investing in ambitious founders leveraging the power of AI. With over $1 billion under management across six seed funds and seven pre-seed funds, portfolio companies include BetterCloud, BitSight, Bowery, Chief, Codecademy (acq: SKILL), FalconX, Firebase (acq: GOOG), Infracommerce (BVMF: IFCM3), MadeiraMadeira, MongoDB (NASDAQ: MDB), Open English, Plastiq, and Splice.
▶33 more co-investors
Crosslink CapitalM13MMC VenturesS32Deerfield Management CompanySanofi VenturesAsset Management Ventures6 Dimensions CapitalVensana CapitalMerck Global Health Innovation Fund4BIO CapitalBreakout VenturesGENERAL INCEPTIONSound VenturesStreamlined VenturesSusa VenturesInnovation EndeavorsSignalFireMaveronBreakthrough Energy VenturesBasementSRB VenturessequelMechanism CapitalForesite CapitalCourtside VenturesTencent HoldingsaMoonDarco CapitalSRI CapitalSharp AlphaGolden Seeds82VS
Firms observed investing alongside Northpond Ventures, from public investor directories. Shared companies are the overlap with Northpond Ventures's recorded portfolio.
Similar investors
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
Qbic is an inter-university venture capital fund that turns technological breakthroughs from its partner universities, research institutes and hospitals into sustainable businesses.
BDC Fund Investments is the fund-of-funds arm of BDC Capital that acts as a limited partner in venture and growth capital funds backing technology-focused Canadian companies. It supports emerging and established fund managers to strengthen Canada's innovation ecosystem.